Subscribe

BriaCell Therapeutics Corp. (BCT.TO)

CAD5.52 +0.30 (+5.75%)
CA TSX Healthcare Biotechnology
Address Bellevue Centre V7T 2X1
West Vancouver, BC, CA
CEO William V. Williams
Website briacell.com
IPO 2012-08-13
ISIN CA1079303071

Explore sections of this company profile

Also trades on NASDAQ Capital Market · BCTX (USD) NASDAQ Capital Market · BCTXW (USD) NASDAQ Global Select · BCTXZ (USD) Toronto Stock Exchange · BCT.TO (CAD)
Description

BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CAD5.52 +0.30 (+5.75%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.2K
Beta
1.64
Float Shares
1.67M
Free Float %
88.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.80% -1.18% -11.75% -3.45% -64.65% -48.67% -89.16% -99.57% -99.16% -99.94% -99.99%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (1 ratings, all time) Buy
Price Targets & DCF
Current price
5.52
DCF (Unlevered) 26.41 +378.4%
DCF (Levered) 34.37 +522.7%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-01 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-6.11
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    —
  • ✗
    EPS growth Biotechnology: +29.7%
    -44.1% Q1'26: +88.9% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    —
  • ✗
    EBIT margin Biotechnology: +0.0%
    —
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: -5,379.0% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +285.7% Q1'26: +938.1% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.63) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 26.41 Current price: 5.52
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jul 2025
actual 		Jul 2026
1 Rev. Ana.
1 EPS Ana. 		Jul 2027
1 Rev. Ana.
1 EPS Ana. 		Jul 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
—
1.50M
1.50M – 1.50M
7.21M
7.21M – 7.21M
+381.0% YoY
25.62M
25.62M – 25.62M
+255.5% YoY
EBITDA
-27.43M
—
— – —
—
— – —
—
— – —
EBIT
-27.54M
—
— – —
—
— – —
—
— – —
Net Income
-26.63M
est: -907.4K (-2,835.0%)
-3.55M
-3.55M – -3.55M
-291.0% YoY
-1.05M
-1.05M – -1.05M
+70.3% YoY
-479.1K
-479.1K – -479.1K
+54.5% YoY
SGA
5.90M
—
— – —
—
— – —
—
— – —
EPS
-62.95
est: -2.14 (-2,835.2%)
-8.38
-8.38 – -8.38
-291.0% YoY
-2.49
-2.49 – -2.49
+70.3% YoY
-1.13
-1.13 – -1.13
+54.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-27 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-26 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-25 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-22 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-21 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-20 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-19 C+ 2/5 5/5 1/5 1/5 1/5 1/5 4/5
2026-05-15 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-14 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-13 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-12 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-11 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-08 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-07 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-06 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-05 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-04 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-05-01 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-30 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-29 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-28 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-27 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-24 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-23 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-22 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-21 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-20 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-17 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
2026-04-16 B- 2/5 5/5 1/5 1/5 1/5 1/5 5/5
Ownership data is not available for this company yet.

Executive team

Top executives
Shares Outstanding
1.88M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
William V. Williams Chief Executive Officer, President & Director 981.0K —
Gadi Levin Chief Financial Officer & Corporate Secretary 737.9K male
Giuseppe Del Priore Chief Medical Officer 679.6K —
Miguel A. Lopez-Lago Chief Scientific Officer 616.9K —
Charles Louis Wiseman FACP Founder, Principal Research Advisor & Member of Scientific Advisory Board 332.4K —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology